Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cutia Therapeutics ( (HK:2487) ) has issued an update.
Cutia Therapeutics has successfully completed the placement of 28,904,000 new shares under a general mandate, raising approximately HK$240.27 million in net proceeds. The funds will be used to advance the company’s research and development pipeline, particularly in areas such as localized adipose accumulation management and skin diseases, as well as to deploy necessary production facilities and equipment.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics is a company incorporated in the Cayman Islands, focusing on healthcare solutions. Its primary products and services include pre-clinical research and development, and clinical trials for localized adipose accumulation management, scalp diseases and care, skin diseases and care, and topical anesthesia.
Average Trading Volume: 1,216,890
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$3.18B
See more data about 2487 stock on TipRanks’ Stock Analysis page.